Portal de investigación
ENSAYO MULTICENTRICO, FASE II DE LENALIDOMIDA, CICLOFOSFAMIDA Y DEXAMETASONA EN PACIENTES CON AMILOIDOSIS SISTEMICA PRIMARIA (AL) DE NUEVO DIAGNOSTICO NO CANDIDATOS A TRASPLANTE.
Datos básicos
- Protocolo:
- LENDEXAL
- EUDRACT:
- 2009-017707-28
- NCT:
- Centro:
- Año de incio:
- 2010
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
Zabaleta, Aintzane; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-184797. 2023
A Critical Appraisal of Absolute Left Ventricular Dimension Thresholds for Intervention in Primary Mitral Regurgitation from a Worldwide Population Perspective.
Lozano-Edo S; (...); Aguero J
Letter. 10.1016/j.echo.2020.09.017. 2021
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML; (...); Vicente V
Article. 10.1016/j.bcmd.2020.102505. 2021
A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Bergua Burgues, Juan Miguel; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189676. 2023
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; (...); Grupo Español de MM
Article. 10.1038/leu.2013.166. 2013
A new precision medicine test to guide personalized treatments decision for acute myeloid leukemia patients.
Ballesteros, J; (...); Robles, A
Meeting Abstract. 2017
A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E; (...); Montesinos P
Article. 10.1002/cncr.35618. 2024
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; (...); PETHEMA Group
Article. 10.1002/cncr.33403. 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Cibeira, MT; (...); Blade, J
Article. 10.1111/bjh.13500. 2015
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Martinez-Cuadron, D; (...); Spanish PETHEMA group
Article. 10.1016/j.leukres.2018.11.006. 2019
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Bergua JM; (...); PETHEMA group
Article. 10.1111/bjh.14107. 2016
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Berard, Emilie; (...); Recher, Christian
Article. 10.1038/s41408-022-00700-x. 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
Solana-Altabella A; (...); Montesinos P
Article. 10.1007/s00277-024-05891-w. 2024
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group
Article. 10.1016/j.leukres.2022.106821. 2022
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study
De la Rubia, J; (...); Gonzalez, MS
Meeting Abstract. 2019
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients.
Article. 10.1007/s00277-012-1596-x. 2012
ANALYSIS OF THE CLINICAL EVOLUTION OF PATIENTS WHO UNDERWENT A SECOND AUTOTRANSPLANTATION OF PERIPHERAL BLOOD FOR RELAPSED MULTIPLE MYELOMA
Garcia, Ruiz Raquel; (...); Arnao, Herraiz Mario
Meeting Abstract. 2020
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.
Pessoa de Magalhães RJ; (...); Orfao A
Article. 10.3324/haematol.2012.067272. 2013
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)
Bergua, J; (...); Montesinos, P
Meeting Abstract. 2018
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.
de la Asunción CS; (...); Navarro D
Article. 10.1002/jmv.28933. 2023
Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience
Article. 10.1038/bmt.2014.107. 2014
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.
Serrano, Josefina; (...); Montesinos, Pau
Article. 10.1016/j.jtct.2025.02.011. 2025
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Jiménez-Ubieto A; (...); Lahuerta JJ
Article. 10.1016/j.bbmt.2017.05.021. 2017
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr
Article. 10.1002/hon.2553. 2018
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.
Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu
Article. 10.1016/j.hemonc.2019.06.001. 2019
Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma
Ubieto, AJ; (...); Lahuerta, JJ
Meeting Abstract. 2018
AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA
Ubieto, AJ; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Redondo, AM; (...); GEL-TAMO
Article. 10.1111/bjh.15713. 2019
Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
De La Fuente, A; (...); Baltasar, P
Meeting Abstract. 2017
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.
Rosiñol L; (...); PETHEMA
Article. 10.3324/haematol.2011.051441. 2012
beta 2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation
Rodriguez-Serrano, M; (...); D'Ocon, P
Article. 10.3389/fphar.2019.00093. 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.
Rosiñol L; (...); Bladé J
Article. 10.1182/blood.2019000241. 2019
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
Blanes M; (...); de la Rubia J
Article. 10.3109/10428194.2014.922182. 2015
BRAF V600E mutation in adult acute lymphoblastic leukemia.
Alonso CM; (...); Sanz Alonso MA
Letter. 10.3109/10428194.2012.733878. 2013
CA125: a new biomarker in patients with Fontan circulation (vol 76, pg 112, 2023)
Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda
Correction. 10.1016/j.rec.2023.03.018. 2023
CA125: a new biomarker in patients with Fontan circulation.
Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda
Article. 10.1016/j.rec.2022.05.029. 2022
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Romero, Alejandra; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-163869. 2022
Clinical features and outcomes of adult patients with single ventricle physiology not undergoing Fontan repair
Gordon, B; (...); Rueda, J
Meeting Abstract. 2020
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)
Vicente, Navarro; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-190296. 2023
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal, Teresa; (...); Montesinos, Pau
Article. 10.1002/cam4.6120. 2023
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing
Ibanez, Mariam; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".
Article. 10.5581/1516-8484.20140020. 2014
COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
Valenzuela, AV; (...); Ramos, IJ
Meeting Abstract. 2018
COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS
Saiz-Rodriguez, M.; (...); Labrador, J.
Meeting Abstract. 2020
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
Arenillas, Leonor; (...); Florensa, Lourdes
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
Calvo, Xavier; (...); Florensa, Lourdes
Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].
Rodríguez-Medina C; (...); Montesinos P
Correction. 10.1016/j.leukres.2020.106388. 2020
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Casado, LF; (...); Castro, A
Article. 10.1111/ejh.13007. 2018
COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, LF; (...); Castro-Gomez, A
Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Puig N; (...); García-Sanz R
Article. 10.1038/leu.2013.217. 2014
CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)
Anglada, LL; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
Hubel, K; (...); Corradini, P
Review. 10.1111/ejh.12362. 2015
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Such E; (...); de la Rubia J
Article. 10.3324/haematol.2011.042572. 2011
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion
Lara, SH; (...); Suarez-Varela, MM
Article. 10.1007/s00408-018-0186-7. 2019
Changes in Adrenoceptor and GRK Expression in Patients With Chronic Pulmonary Regurgitation.
Rodríguez-Serrano M; (...); Martínez-Dolz L
Article. 10.1016/j.rec.2018.05.030. 2019
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study
Kayser, S; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-111768. 2018
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Kayser S; (...); Levis MJ
Article. 10.3324/haematol.2021.278645. 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112974. 2018
Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Angenendt, L; (...); Schliemann, C
Article. 10.1200/JCO.19.00416. 2019
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; (...); Vicente V
Article. 10.1038/s41598-019-53209-y. 2019
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE
Jarque, Ramos, I; (...); Shepherd, Moreno J.
Meeting Abstract. 2020
DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN
Andrade, R.; (...); Shepherd, J.
Meeting Abstract. 2019
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Bonanad S; (...); GAH Group
Article. 10.1016/j.jgo.2015.03.003. 2015
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Spanish PETHEMA Grp
Article. 10.4084/MJHID.2019.016. 2019
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125557. 2019
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU; (...); Montesinos P
Article. 10.1007/s00277-024-05840-7. 2024
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/17512433.2023.2174523. 2023
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.1007/s00277-020-04186-0. 2020
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant
Solano C; (...); Bow EJ
Article. 10.1111/myc.12552. 2017
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome
Cañigral C; (...); Sanz MA
Letter. 10.1007/s00277-013-1970-3. 2014
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI
Lopez, TJG; (...); Hermida, G.
Meeting Abstract. 2017
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators
Article. 10.1001/jama.2019.9053. 2019
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study
de la Rubia, Javier; (...); Sanz, Miguel A.
Article. 10.1016/j.transci.2010.09.018. 2010
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY
Martin, EMD; (...); Castera, MJT
Meeting Abstract. 2018
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
González-López TJ; (...); González-Porras JR
Article. 10.1111/ejh.12725. 2016
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/14728214.2021.2009800. 2022
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Essential ECG clues in patients with congenital heart disease and arrhythmias
Cano, O; (...); Martinez-Dolz, L
Article. 10.1016/j.jelectrocard.2016.08.005. 2017
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2014-0042. 2014
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2011-0391. 2012
Evaluation of a near-zero fluoroscopic approach for catheter ablation in patients with congenital heart disease
Cano, O; (...); Mart?nez-Dolz, L
Article. 10.1007/s10840-018-0467-3. 2019
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador, Jorge; (...); Montesinos, Pau
Article. 10.1002/cncr.35431. 2024
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Gudiol C; (...); de la Cámara R
Article. 10.1016/j.eimc.2019.01.013. 2020
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Fontan Circulation in Adult Patients: Acoustic Radiation Force Impulse Elastography as a Useful Tool for Liver Assessment.
Melero-Ferrer JL; (...); Rueda-Soriano J
Article. 10.1177/2150135114530172. 2014
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; (...); Gutiérrez NC
Article. 10.3324/haematol.2011.060780. 2012
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Ballesta-López O; (...); Montesinos P
Review. 10.2217/fon-2020-0700. 2020
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Haplotypes of the endothelial protein C receptor gene and circulating protein C levels
Martos, Laura; (...); Espana, Francisco
Article. 10.1016/j.thromres.2012.08.026. 2012
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Garcia-Marco, JA; (...); GELLC Study Grp
Article. 10.3324/haematol.2018.204891. 2019
High-Bandpass Filters in Electrocardiography: Source of Error in the Interpretation of the ST Segment.
Buendía-Fuentes F; (...); Palencia-Pérez MA
Article. 10.5402/2012/706217. 2012
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Paiva B; (...); PETHEMA
Article. 10.1182/blood-2011-07-370460. 2012
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta, Pau; (...); Bosch, Francesc
Article. 10.1016/j.eclinm.2024.102642. 2024
IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP
Rey, Bua Beatriz; (...); Martin, A.
Meeting Abstract. 2020
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
Gonzalez-Lopez, TJ; (...); Porras, JRG
Meeting Abstract. 2017
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112495. 2018
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of the Conditioning Regimen in Patients With Multiple Myeloma Who Undergo Autologous Transplantation
de la Rubia, Javier, Lahuerta, Juan J.
Article. 10.1200/JCO.2010.33.7832. 2011
Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia
Barba P; (...); Ribera JM
Article. 10.3109/10428194.2015.1014365. 2015
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, Sabine; (...); Schlenk, Richard F.
Article. 10.3324/haematol.2022.282127. 2023
Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation
Article. 10.1016/j.bbmt.2013.10.016. 2014
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E; (...); Ayala R
Article. 10.1111/bjh.16432. 2020
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE
Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)
San Segundo, LY; (...); Solano, C.
Meeting Abstract. 2017
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Pinana JL; (...); Sanz MA
Article. 10.1007/s00277-013-1872-4. 2014
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-122237. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study
Boluda, Blanca; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD
De la Fuente, A.; (...); Montesinos, P.
Meeting Abstract. 2019
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; (...); de la Rubia J
Article. 10.1016/j.bbmt.2012.08.009. 2013
Invasive yeast infections in neutropenic patients
Camps, IR, Jarque, I
Review. 10.1016/j.riam.2015.11.001. 2016
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker L; (...); FIRST Trial Team
Article. 10.1056/NEJMoa1402551. 2014
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP
Baile, M.; (...); Martin, A. A.
Meeting Abstract. 2017
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; (...); San Miguel JF
Article. 10.1056/NEJMoa1300439. 2013
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Long term outcome of single ventricle physiology with pulmonary restriction not undergoing Fontan repair
Buendia, F; (...); Dos, L
Meeting Abstract. 2020
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1038/leu.2017.178. 2018
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato
Article. 10.1016/j.jtct.2020.12.029. 2021
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Martinez-Lopez, Joaquin; (...); Jose Lahuerta, Juan
Article. 10.1182/blood-2011-01-332320. 2011
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Recher, Christian; (...); Montesinos, Pau
Article. 10.1038/s41375-021-01425-9. 2022
Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.
Mingot-Castellano ME; (...); González Porras JR
Article. 10.1155/2019/4621416. 2019
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
Calleja-Panero, JL; (...); Gil, A
Article. 10.17235/reed.2020.6895/2020. 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; (...); Zeidan AM
Article. 10.1038/s41375-020-0783-3. 2020
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Massive Primary Mitral Regurgitation Due to Chordae Rupture: Treatment With New-Generation Edge-to-Edge Repair Devices.
Vilchez-Tschischke JP; (...); Diez-Gil JL
Editorial Material. 10.1016/j.jcin.2020.12.026. 2021
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; (...); Montesinos P
Article. 10.1182/bloodadvances.2020003195. 2021
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG; (...); Bahlis NJ
Article. 10.1056/NEJMoa2303194. 2023
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas, Claudia; (...); On Behalf Of Pethema Group
Article. 10.3390/cancers15020438. 2023
Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target
Medina, Daniel; (...); Crespo, Marta
Meeting Abstract. 10.1182/blood-2023-185683. 2023
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Paiva B; (...); San Miguel JF
Article. 10.1016/j.ajpath.2012.07.020. 2012
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES
Primo, D.; (...); Ballesteros, J.
Meeting Abstract. 2017
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
Noninvasive Liver Assessment in Adult Patients With Fontan Circulation Using Acoustic Radiation Force Impulse Elastography and Hepatic Magnetic Resonance Imaging.
Buendia-Fuentes, F; (...); Martinez-Dolz, L
Article. 10.1177/2150135117732674. 2018
OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
Montesinos, P.; (...); Sanz, M.
Meeting Abstract. 2017
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; (...); Giebel S
Article. 10.1016/j.clml.2019.09.616. 2020
Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Kayser S; (...); Montesinos P
Article. 10.1038/s41375-020-0758-4. 2020
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Article. 10.3324/haematol.2022.282506. 2024
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Shallis, RM; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-119755. 2018
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, JF; (...); Richardson, PG
Article. 10.1016/S1470-2045(14)70440-1. 2014
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Parasitic Infections in Hematopoietic Stem Cell Transplantation.
Article. 10.4084/MJHID.2016.035. 2016
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Rodriguez-Medina, C; (...); Fernandez, PM
Article. 10.1016/j.leukres.2020.106352. 2020
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine
Bennett TA; (...); Ballesteros J
Article. 10.1016/j.clml.2013.11.006. 2014
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Robak, T; (...); Jolles, S
Article. 10.1182/bloodadvances.2020002003. 2020
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Cabrero, M; (...); Caballero, D
Article. 10.1016/j.bbmt.2016.10.003. 2017
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1007/s00277-013-1914-y. 2014
PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review
Sobas, M; (...); Montesinos, P
Review. 10.3390/cancers12051313. 2020
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1007/s40261-019-00881-7. 2020
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1080/17474086.2020.1818559. 2020
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments
Ballesteros, J; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-115849. 2018
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters
Herrera Lara S; (...); Morales Suárez-Varela M
Article. 10.1007/s00408-017-0032-3. 2017
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125580. 2019
PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Abrisqueta, Pau; (...); Bosch, Francesc
Meeting Abstract. 10.1182/blood-2019-128470. 2019
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry
Villegas, A; (...); Urbano, A
Article. 10.1007/s00277-017-3059-x. 2017
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
Uriel Suarez, Edwin; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-167365. 2022
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA
LLop, M.; (...); Angel Sanz, M.
Article. 2013
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu
Article. 10.1002/cam4.1217. 2017
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; (...); Sanz MA
Article. 10.1016/j.jmoldx.2012.06.006. 2012
Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O; (...); PETHEMA and PALG Groups
Article. 10.1080/10428194.2019.1607327. 2019
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
Aperla; (...); Llopis JE
Article. 10.1177/0267659111412999. 2011
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; (...); López-Guillermo A
Article. 10.1007/s00277-020-03918-6. 2020
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Jarque, Isidro; (...); Peffault, de latour Regis
Meeting Abstract. 2020
RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
Parra, ML; (...); Martin, A. A.
Meeting Abstract. 2017
Role of autologous bone marrow transplant in multiple myeloma.
Article. 10.1097/CCO.0b013e328358f686. 2012
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
Paiva, B; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-113299. 2018
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Robak, Tadeusz; (...); Jolles, Stephen
Meeting Abstract. 10.1182/blood-2019-129839. 2019
Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL
Yanez, L; (...); Bosch, F
Meeting Abstract. 2019
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1007/s00277-018-3304-y. 2018
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Vives, Susana; (...); PETHEMA Grp
Article. 10.3390/cancers16234028. 2024
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Espinoza, Marcela; (...); Martinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-185288. 2023
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Jimenez-Ubieto, A; (...); Lahuerta, JJ
Letter. 10.1038/s41409-018-0096-6. 2018
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Roman, E; (...); Gorriz, JL
Review. 10.1016/j.nefro.2017.01.006. 2017
Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry
Tura, G. Teixido; (...); Cabrera, F.
Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Villegas A; (...); Urbano-Ispizua Á
Editorial Material. 10.1016/j.medcli.2015.12.012. 2016
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Rosiñol L; (...); Programa para el Estudio y la Terapéutica de las Hemopatías Malignas
Article. 10.1182/blood-2012-02-408922. 2012
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E; (...); Zabaleta A
Article. 10.1182/bloodadvances.2024013212. 2024
THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG
Porras, JRG; (...); Bastida, J. M.
Meeting Abstract. 2017
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose
Article. 10.3390/cancers16244189. 2024
THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Time course and predictors for neoaortic root dilatation and neoaortic valve regurgitation during adult life after arterial switch operation.
Rueda Soriano, Joaquin; (...); Gallego, Pastora
Article. 10.1016/j.recesp.2020.01.031. 2020
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; (...); Carpio N
Article. 10.1016/j.transci.2019.09.011. 2020
Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation
Article. 10.2450/2015.0195-14. 2015
Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment
Montesinos P; (...); Sanz MÁ
Article. 10.1016/j.riam.2014.10.003. 2015
Treatment of multiple myeloma in the elderly: realities and hopes
De La Rubia, Javier, Sanz, Miguel A.
Review. 10.3109/10428194.2010.530361. 2011
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189800. 2023
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
Lloret-Madrid, Pilar; (...); Montesinos, Pau
Article. 10.1002/cncr.35696. 2025
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1016/j.blre.2020.100675. 2020
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Garcia-Marco, JA; (...); Bosch, F
Editorial Material. 10.1016/j.medcli.2016.12.030. 2017
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; (...); García-Frade LJ
Article. 10.1111/ejh.13370. 2020
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP; (...); Montesinos P
Letter. 10.3324/haematol.2023.284601. 2024
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
Montesinos, P; (...); Sanz, MA
Meeting Abstract. 2017
Validation of the usefulness of 2-dimensional strain parameters to exclude acute rejection after heart transplantation: a multicenter study.
Goirigolzarri Artaza, Josebe; (...); Segovia Cubero, Javier
Article. 10.1016/j.recesp.2020.01.033. 2020
Value of the Electrocardiogram as a Predictor of Right Ventricular Dysfunction in Patients With Chronic Right Ventricular Volume Overload.
Alonso P; (...); Salvador A
Article. 10.1016/j.rec.2014.04.019. 2015
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Dachs, LR; (...); Blade, J
Meeting Abstract. 10.1182/blood-2018-99-111924. 2018
WT1 isoform expression pattern in acute myeloid leukemia.
Article. 10.1016/j.leukres.2013.10.009. 2013
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Garcia-Sanz, R; (...); Mateos, MV
Article. 10.3324/haematol.2015.128439. 2015